Plan Ahead Product Launch

RNS Number:5617L
Biofusion PLC
11 January 2008


For immediate release                                           11 January 2008


                                 BIOFUSION PLC
                         ("Biofusion" or "the Company")

               LIFESTYLE CHOICES' PLAN AHEAD TEST LAUNCHED IN US
                      - Biological Clock Test for Women -

Biofusion plc (AIM: BFN), the university IP commercialisation company that turns
world class research into business, is pleased to note that Lifestyle Choices'
Plan Ahead(TM) test, which helps measure a woman's ovarian reserves, has been
launched in the US by Repromedix Corp ("Repromedix"), its previously undisclosed
US partner, a leading national diagnostic laboratory for fertility testing
company.

Lifestyle Choices Limited ("Lifestyle Choices"), Biofusion's female fertility
spin-out company, announced in October 2007 that it had signed a licence
agreement with an undisclosed leading US reproductive diagnostics company, for
the exclusive rights to sell Plan Ahead(TM) in North America and Canada.

Plan Ahead(TM) is a blood test that provides an assessment of a woman's egg 
supply by combining multiple factors including the measurement of ovary-related
hormones AMH, Inhibin B, and FSH with innovative and proprietary technology.

Repromedix announced yesterday that it had launched Plan Ahead(TM) in Boston,
Atlanta, Corona (CA), Norfolk (VA), Denver and Colorado Springs via strategic
partnerships with the following renowned fertility clinics: Boston IVF, Georgia
Reproductive Specialists, The Jones Institute for Reproductive Medicine (VA),
Reproductive Medicine & Fertility Center (CO), and the Corona Institute for
Reproductive Medicine & Fertility (CA).

Repromedix expects to make the test available in New York, Chicago, Los Angeles,
Miami, Fort Lauderdale, Columbia (SC), Raleigh, Indianapolis and Dallas in the
near future. The suggested cost of the Plan Ahead(TM) test is $350. Women
interested in obtaining the Plan Ahead(TM) test are encouraged to visit the
Company's website: www.planaheadtest.com.

The window of opportunity for a woman to have children by natural conception is
dependent upon an adequate supply of eggs which inevitably declines as a woman
ages and her "biological clock ticks". Plan Ahead(TM) enables a woman to compare
her estimated egg supply with the normal range expected for women of the same
age.

Commenting on the announcement, David Baynes, Chief Executive Officer of
Biofusion, said: "We are delighted that the Plan Ahead(TM) test has now been
launched in the US. This is a significant achievement for Lifestyle Choices and
look forward to its success in the US and other territories."

Dr. Michael M. Alper, Harvard Medical School professor, and the medical director
and co-founder of Boston IVF, an internationally renowned fertility treatment
center, commented: "As more and more women delay pregnancy until their 30s and
even their 40s, there is an urgent need for an accurate early assessment of
their fertility. Unfortunately, we see far too many women late in the process
when time is of the essence. The fertility field has been waiting for a test
like this, and we are delighted to be the first practice to partner with
Repromedix in providing this innovative test to women in the greater Boston
area."

Paul Kowalski, President and VP of Sales at Repromedix, said: "A recent survey
indicates that over 80% of women between the ages of 25 to 44 believe that the
risk of fertility loss begins at age 35, while many experts believe the risk
begins much earlier. We believe that the Plan Ahead(TM) test will provide an
important tool for better education and lead to early diagnosis of potential
fertility-related issues."


For further information about Biofusion, please contact:

Biofusion                                                     +44 (0)114 275 5555
David Baynes / Stuart Gall

Buchanan Communications                                       +44 (0)20 7466 5000
Mary-Jane Johnson / Lisa Baderoon / Catherine
Breen

Nomura Code                                                   +44 (0)20 7776 1200
Phil Walker / Clare Terlouw


About Biofusion


Biofusion was established in 2002 to commercialise university-generated IP.
Biofusion has signed long term agreements with two of the UK's top ten research
intensive universities (University of Sheffield and Cardiff University) giving a
combined R&D spend attributable to Biofusion of approximately �114 million a
year. The Company has a portfolio of over 20 spin-out companies.

Biofusion's first agreement was a ten-year exclusive arrangement with the
University of Sheffield for the commercialisation of IP owned by the University
in the area of medical life sciences. Biofusion has shareholdings in a portfolio
of Sheffield University spin-out companies including Asterion, Axordia,
Biohydrogen, Diurnal and Phase Focus. The University of Sheffield was ranked 5th
in the UK for the quality of its life sciences research and will be spending an
estimated �0.5bn of research funding over the lifetime over the life of the
Sheffield Agreement.

In January 2007, Biofusion completed a long-term exclusive agreement with
Cardiff University, to commercialise 100% of all Cardiff University's
research-generated IP. Biofusion has shareholdings in a portfolio of Cardiff
University spin-out companies including Abcellute, Q-Chip and Morvus. Cardiff
University was ranked 7th in the UK in the most recent research rankings and
will be spending over �1.0bn of research funding over the lifetime over the life
of the Cardiff Agreement.


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCGUUCPGUPRGBU
Biofusion (LSE:BFN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024